RVU GPW sWIG80 Periodic report · PAP Biznes
Ryvu Therapeutics (RVU) · Q2 2026 results
Share price: 17.20 zł · 2026-11-10
Results Q2 2026 vs Q2 2025 · year over year · published 17 Sep 2026 and 18 Sep 2025
Loss per share narrowed year on year. The report's language is unchanged.
Only a basic analysis is available for this company at the moment.
1 · Numbers
Loss narrowed
EPS vs Q2 2025
EPS -1.10 vs -2.55
2 · How the report reads
Unchanged
Language tone vs last period
Report language: typical for a company report — about as upbeat as in Q2 2025.
Weak signal: formal report language, not a call.
3 · What stood out
Ryvu Therapeutics started patient recruitment in five countries for the REMARK study to evaluate RVU120 as a monotherapy for low-risk myelodysplastic syndromes across 25 centers for approximately 40 patients.
Read between the lines
No major shifts flagged this period.
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q2 2026. Ring: Q2 2025.
Typical for a company report — about as upbeat as in Q2 2025. Periodic reports carry legally required risk wording, so their tone moves little and is a weak signal.
Full figures
PLN · PAP Biznes report (2026-09-17)
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | 28.9M | — | |
| EBITDA | -24.7M | -60.6M | Loss narrowed |
| Operating income | -28.8M | — | |
| Net income | -25.7M | — | |
| EPS | -1.10 | -2.55 | Loss narrowed |
| P/E | 12-mo loss | 12-mo loss | — |
Topics
Topics are drawn from the full report text, not management commentary.
Most discussed now
- New The Polish original shall be referred to in matters of interpretation.
- New Ryvu Therapeutics has reviewed the interim condensed financial statements of Ryvu Therapeutics S.A.
Faded since Q2 2025
- Dropped Until the second half of 2026, which will allow the Company to focus on the implementation of the clinical program
- Dropped Silencing the identified target led to the selective death of tumor cells derived from patients, while simultaneously sparing healthy…
- Dropped RVU120 shows a strong synergistic effect in combination with venetoclax (VEN), supporting the overcoming of resistance to VEN in the…
- Dropped In part A, cohort 1 will assess the impact of RVU120 as a monotherapy in patients who were previously treated with a JAK inhibitor or are…
Latest announcements
Official filings, newest first.
- Zawarcie umowy o dofinansowanie z Narodowym Centrum Badań i Rozwoju / Conclusion of a grant agreement with the National Centre for Research and Development · ESPI 22/2026
- Half-year report · ESPI periodic
- Rekomendowanie projektu Ryvu do dofinansowania przez Polską Agencję Rozwoju Przedsiębiorczości/Recommendation of Ryvu's project for funding by the Polish Agency for Enterprise Development · ESPI 21/2026
- Uruchomienie przez Ryvu wyspecjalizowanego biznesu usługowego w obszarze wczesnego rozwoju klinicznego pod marką "Keelira" / Ryvu launches a specialized early clinical development services business under the "Keelira" brand · ESPI 20/2026
- Rekomendowanie projektu Ryvu do dofinansowania przez Narodowe Centrum Badań i Rozwoju / Ryvu's project recommended for funding by the National Centre for Research and Development · ESPI 19/2026
- Zawarcie z Grupą Menarini aneksu do globalnej umowy licencyjnej dotyczącego dalszego rozwoju klinicznego dapolsertibu / Conclusion of an amendment to the global license agreement with Menarini Group concerning the further clinical development of dapolsert · ESPI 18/2026
- Korekta raportu bieżącego nr 16/2026 z dnia 25 czerwca 2026 r. - sprostowanie błędu pisarskiego / Correction of Current Report No. 16/2026 dated June 25th, 2026 - correction of a clerical error · ESPI 16/2026
- Powołanie Członków Zarządu Ryvu Therapeutics S.A. na nową kadencję / Appointment of Management Board Members of Ryvu Therapeutics S.A. for a new term of office · ESPI 17/2026